Camrelizumab Combined With Gemcitabine and Albumin-Bound Paclitaxel for Neoadjuvant Therapy in the Treatment of Progressive Gallbladder Cancer: A Case Report

Abstract

BackgroundThe roles of immune checkpoint inhibitors in the treatment of gallbladder cancer are still unclear and challenged by controversial findings. Recent research has shown that immune checkpoint inhibitors in combination with chemotherapy may alleviate disease progression.Case SummaryA 45-year-old female patient with gallbladder cancer accompanied by multiple abdominal lymph node metastasis was treated with camrelizumab combined with paclitaxel for injection (albumin-bound) and gemcitabine (AG) to downstage the tumor before a radical surgery could be performed. The postoperative quality of life was superior to the preoperative level.ConclusionCamrelizumab + AG offers a new therapeutic option for gallbladder cancer with multiple abdominal lymph node metastasis, which, however, warrants further validation in clinical trials.

Progress in gallbladder cancer with lymph node metastasis

“…Wu et al. showed that camrelizumab + AG could be a new treatment option for GBC with multiple abdominal LNM ( 73 , 74 ). The ongoing European phase III clinical trial (ACTICCA-1 study, NCT02170090) is exploring the efficacy of adjuvant therapy with the GC regimen.…”